HepaLipa-Study: Observing the influence of an IL-17 inhibition on liver steatosis and inflammation.

HepaLipa-Study: Observing the influence of an IL-17 inhibition on liver steatosis and inflammation. - HepaLipa

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00027573

Enrollment

160

Registered

2022-01-14

Start date

2022-04-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

K76.0 K75.8

Interventions

Group 1: Patients with psoriasis, psoriatic arthritis or ankylosing spondylitis for whom a new biological therapy is started undergo hepatologic examination (Fib4, NAFLD fibrosis score, transient elas

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with an existing indication for drug therapy of psoriasis, psoriatic arthritis or ankylosing spondylitis.

Exclusion criteria

Exclusion criteria: other liver diseases (ethyl toxic, viral, secondary), acutely life-threatening diseases, pregnant women, known drug abuse or participation in a drug substitution program, inability to give consent

Design outcomes

Primary

Measure	Time frame
Observation of the immune response (Th17 / Treg ratio) and the course of NAFLD (Fib4 Score, NAFLD-Fibrosis Score, CK18, hyaluronic acid) under therapy with IL-17 antagonists.	—

Countries

Germany

Contacts

Public ContactGiuseppe Rusignuolo

Universitätsklinikum Freiburg; Klinik für Innere Medizin II

giuseppe.rusignuolo@uniklinik-freiburg.de+4976127034010

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026